Application of auronafine in preparation of mismatch modification defect or ARID1A defect tumor drugs

Through the competitive binding of aristophen with TOPBP1 and the combination of MLH1/ARID1A inhibitors, the side effects and drug resistance of aristophen in anti-cancer treatment were solved, and the killing effect on specific tumor types was significantly improved, achieving the Low-dose and efficient tumor treatment.

CN118987020AActive Publication Date: 2024-11-22TIANJIN MEDICAL UNIV

Patent Information

Application Number
CN202411166434.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-22
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

The existing ananovolin has serious side effects and drug resistance problems in anti-cancer treatment, and its therapeutic effect on MMRD and ARID1A defective tumors is limited, making it difficult to effectively kill tumor cells.

Method used

By finding that Kannoxophen can compete to bind TOPBP1, inhibit the ATR signaling pathway, and increase the replication pressure of tumor cells, thereby killing ARID1A-deficient or mismatch repair-deficient tumor cells at lower doses, combining MLH1 inhibitors or ARID1A inhibitors, Form a combination of drugs to improve therapeutic effects.

Benefits of technology

It significantly improves the sensitivity to ARID1A-deficient or MLH1-deficient tumors, enhances tumor suppression effect, reduces side effects, achieves low-dose and efficient anti-tumor treatment, and promotes the high efficacy and low-side effects application of chemotherapy drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987020A_ABST
    Figure CN118987020A_ABST
Patent Text Reader

Abstract

The invention requests to protect application of auronafine in preparation of drugs for treating mismatch repair defects and ARID1A gene deletion tumors, in particular to application of auronafine in preparation of drugs for treating ARID1A <- / -> and MLH1 <- / -> tumors. According to the invention, the limitation of side effects and drug resistance of Jinnofen is overcome. It is found that the auronafine can be specifically combined with TOPBP1 protein to interfere with the interaction of the TOPBP1 protein with PHF8 and FANCJ, replication pressure response is inhibited, and especially in tumor cells with ARID1A defect or MLH1 defect, an enhanced anti-tumor effect is shown. The action mechanism does not depend on traditional TrxR inhibition, provides a new view angle for Jinnofen treatment, and provides possibility for precise medical treatment and new use of old medicines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical background:

[0001] Cancer treatment is one of the major challenges in the medical field, and researchers have been looking for more effective treatment strategies. Auranofin, a platinum compound, has shown the potential to induce apoptosis of cancer cells by binding to DNA to interfere with replication and transcription processes in anticancer treatment, but its clinical application is limited by the serious side effects that may be caused, such as kidney, neurotoxicity and hearing damage, as well as the problem of cancer cell resistance that may be caused by long-term use. These problems not only affect the quality of life of patients, but may also reduce the effectiveness of treatment, making auranofin face challenges in practical application.

[0002] During the occurrence and development of tumors, replication stress has an important impact on the survival and proliferation of tumor cells. During the rapid proliferation of tumor cells, their DNA replication machinery faces endogenous damage, leading to the generation of replication stress. This stress is a key factor for cells to maintain genomic stability. Due to defects in the G1 / S checkpoint, tumor cells are more prone to errors during DNA replication, and thus rely more on effective replication stress response mechanisms to avoid the accumulation of genomic mutations. If replication stress is not effectively managed, tumor cells may die due to mitotic collapse. Therefore, the molecular mechanism of replication stress is a vulnerable point for the survival of tumor cells and provides a potential target for the development of new tumor treatment strategies.

[0003] The occurrence, development and proliferation of tumor cells are usually related to genetic defects, especially closely related to mismatch repair deficiency (MMRD) or ARID1A (AT-rich interactive domain-containing protein 1A). MMRD is a genetic defect, which refers to the impaired function of the intracellular mismatch repair (MMR) system, resulting in the inability to correct DNA base pairing errors in a timely manner. MMRD tumors are clinically characterized by high microsatellite instability (MSI-H), which leads to the occurrence and development of tumors. The treatment of MMRD tumors has always been a challenge, and traditional treatments have limited effects. MMRD defects are usually caused by gene deletions including MLH1, MSH2, MSH6, and PMS2. Among them, the mutation frequency of MLH1 is relatively high, with a mutation rate of about 1.28% in all cancers, among which colon cancer, lung cancer, endometrial cancer, breast invasive ductal carcinoma and conventional glioblastoma multiforme have the highest mutation incidence. However, there are not many good targeted treatment strategies for these MMRD tumors.

[0004] ARID1A is a gene that plays a key role in the process of DNA chromatin remodeling. ARID1A is a component of the SWI / SNF chromatin remodeling complex and is involved in regulating gene expression, DNA repair, and cell cycle control. Mutations in ARID1A often lead to its loss of function, affecting chromatin remodeling and gene expression regulation, thereby promoting tumorigenesis. About 6% of human cancer patients carry inactivating mutations in the ARID1A gene. Some cancer types show the highest frequency of ARID1A inactivating mutations and loss of expression, including ovarian cancer (about 50%), endometrial cancer (about 37%), gastric cancer (20-30%), bladder cancer (about 20%), hepatocellular carcinoma (about 14%), melanoma (about 12%), colorectal cancer (about 9%), and lung cancer (about 8%). So how to provide more effective targeted treatment for cancer patients with ARID1A mutations is one of the current focuses of clinical research.

[0005] The present invention creatively discovered that auranofin can competitively bind to TOPBP1, and by inhibiting the activation of the ATR signaling pathway, the replication stress generated by the frequent replication of tumor cells cannot be effectively alleviated, which ultimately leads to the death of tumor cells. The present invention creatively discovered that in tumor cells with ARID1A defects or mismatch repair pathway defects, the use of auranofin for treatment will increase the sensitivity of the tumor. The use of auranofin at a lower dose can kill tumor cells and increase the survival of patients, overcoming the disadvantages of auranofin's large side effects and drug resistance. Summary of the invention:

[0006] The present invention provides a use of a competitive inhibitor of TOPBP1 in the preparation of a pharmaceutical composition for treating and / or improving tumors, wherein the tumor is selected from:

[0007] i) Mismatch repair deficient (MMRD) tumors;

[0008] or ii) ARID1A-deficient tumors.

[0009] Furthermore, the mismatch repair deficient tumor is an MLH1 deficient tumor.

[0010] Furthermore, the binding site of the competitive inhibitor of TOPBP1 is the BRCT7-8 pocket of TOPBP1.

[0011] Furthermore, the competitive inhibitor of TOPBP1 has the effect of destroying the binding of PHF8-TOPBP1 and FANCJ-TOPBP1.

[0012] Furthermore, the competitive inhibitor of TOPBP1 is auranofin.

[0013] A second aspect of the present invention provides a treatment device, characterized in that it comprises module i) and module ii):

[0014] Module i) is a detection module, and the module i) includes detecting whether the in vitro sample is ARID1A defect, MLH1 defect,

[0015] Required testing reagents;

[0016] Module ii) is an identification and administration module, wherein the competitive inhibitor of TOPBP1 is administered to the ex vivo sample of the patient identified as ARID1A-deficient or MLH1-deficient in module i).

[0017] Furthermore, the detection reagent in module i) of the device is a biomolecule that specifically hybridizes with the ARID1A or MLH1 gene, an expression product of the ARID1A or MLH1 gene, and / or a detection reagent that uses the ARID1A or MLH1 gene as a detection target.

[0018] Further, in module ii) of the device, the competitive inhibitor of TOPBP1 has the function of binding to the BRCT7-8 pocket of TOPBP1 or the competitive inhibitor of TOPBP1 has the function of destroying PHF8-TOPBP1,

[0019] The effect of FANCJ-TOPBP1 binding; preferably, the competitive inhibitor of TOPBP1 is auranofin.

[0020] The third aspect of the present invention provides the use of a reagent for detecting a biomarker in the preparation of a kit for predicting the anti-tumor efficacy of Auranofin, wherein the biomarker is:

[0021] i) ARID1A or MLH1 gene; or

[0022] ii) ARID1A or MLH1 gene expression products.

[0023] Furthermore, the tumor includes colon cancer, lung cancer, endometrial cancer, invasive ductal carcinoma of the breast, conventional glioblastoma multiforme, ovarian cancer, gastric cancer, bladder cancer, hepatocellular carcinoma, melanoma, and / or colorectal cancer.

[0024] The fourth aspect of the present invention provides a pharmaceutical composition comprising component 1 and component 2.

[0025] The component 1 is auranofin;

[0026] The component 2 is a MLH1 inhibitor or an ARID1A inhibitor.

[0027] A fifth aspect of the present invention provides the use of auranofin and an MLH1 inhibitor and / or an ARID1A inhibitor in the preparation of an anti-tumor drug, wherein the tumor is an ARID1A-deficient or MLH1-deficient tumor.

[0028] The present invention has the following advantages:

[0029] 1. Discovery of a new mechanism of action of auranofin: This invention breaks the limitation that auranofin traditionally exerts its pharmacological effect by inhibiting thioredoxin reductase (TrxR), and reveals that auranofin, as a small molecule compound, can bind to the BRCT7-8 pocket of TOPBP1, occupying the PHF8 and

[0030] The key binding site of FANCJ, thereby inhibiting the formation of PHF8-TOPBP1 and FANCJ-TOPBP1 complexes.

[0031] 2. It was found that auranofin affects replication stress response: Auranofin inhibits the activation of ATR signaling and the accumulation of RPA on damaged chromatin by interfering with the function of TOPBP1, which is crucial for the regulation of replication stress and the cell's response to DNA damage.

[0032] 3. It was found that auranofin has enhanced anti-tumor activity in a specific genetic background: Auranofin showed a synthetic lethal effect on colorectal cancer with mismatch repair defects, such as MLH1-deficient colorectal cancer or ARID1A-deficient colorectal cancer.

[0033] 4. Auranofin exhibits enhanced tumor suppressor effects in the treatment of ARID1A-deficient or MLH1-deficient tumors:

[0034] In cell experiments and xenograft animal models, when auranofin was co-treated with ARID1A-deficient or MLH1-deficient colorectal cancer cells, it showed a more significant tumor growth inhibitory effect than either treatment alone.

[0035] 5. The present invention creatively discovered that auranofin, which has high side effects and drug resistance in treatment, has good sensitivity to tumor patients carrying ARID1A or MLH1 mutations. Therefore, the application of auranofin's low-dose anti-tumor effect in achieving precision medicine will be developed, which will also realize the new use of old drugs and promote the therapeutic potential of chemotherapy drugs with high efficacy and low side effects.

[0036] 6. Potential for clinical application: Since auranofin is already an FDA-approved drug for the treatment of rheumatoid arthritis, the application of the drug developed in the present invention in the preparation of tumor drugs may accelerate the clinical transformation process. Description of the drawings:

[0038] Figure 1A The biolayer interferometry (BLI) method was used to quantitatively analyze the binding affinity between auranofin and His-tagged recombinant BRCT7-8 purified from Escherichia coli cells; the figure includes the BLI sensorgram and the determination results of the dissociation constant (Kd); the black line in the figure represents the fitting curve, and the colored line represents the original data.

[0039] Figure 1B Shown is a flow chart of the BLI experiment used to examine the inhibitory effect of auranofin on BRCT7-8 binding to PHF8 / APS peptide and FANCJ peptide containing phosphorylated Thr1133 (pFANCJ).

[0040] Figure 1C A diagram of the chemical structure of auranofin is shown.

[0041] Figure 1D BLI analysis demonstrated the inhibitory effect of auranofin on the binding of BRCT7-8 to PHF8 / APS peptide and pFANCJ; the figure shows the incubation results of His-tagged BRCT7-8 at different auranofin concentrations, the black line is the fitting curve, and the colored line is the original data.

[0042] Figure 2A Shown are immunoprecipitation (IP) and immunoblotting (IB) experiments using cell lysates of HeLa cells expressing FLAG-TOPBP1 treated with auranofin at different doses for 2 h.

[0043] Figure 2B Shown is a Co-IP assay that detected changes in TOPBP1-PHF8 and TOPBP1-FANCJ interactions in cell lysates of HeLa cells treated with auranofin (2 μM, 2 h).

[0044] Figure 2C Co-IP analysis compared the expression of auranofin, PMX464, and piperlongumine in HeLa cells treated with

[0045] Differences in TOPBP1-PHF8 and TOPBP1-FANCJ interactions.

[0046] Figure 2D Shown are the results of BLI analysis of auranofin binding to recombinant BRCT7-8 / Wt and BRCT7-8 / F1411A, including BLI sensorgrams and dissociation constants (Kd).

[0047] Figure 2EA schematic diagram of the prime editing system and representative sequencing results of the edited genome of HeLa cells F1411A are shown, including the sequence of the key elements of epegRNA.

[0048] Figure 2F Co-IP analysis was performed to detect the binding of TOPBP1 to PHF8 and FANCJ in wild-type and F1411A endogenously edited HeLa cells treated with DMSO or auranofin.

[0049] Figure 3A Figure 3 TOPBP1 foci formation was detected under physiological conditions by immunostaining and confocal microscopy analysis. Cells were pre-extracted and fixed in the presence or absence of NAC (50 μM) 3 h after treatment with auranofin, PMX464, and piperlongumine.

[0050] Figure 3B We present the analysis of TOPBP1 under conditions of replication stress (CPT) by immunostaining and confocal microscopy.

[0051] To investigate the formation of foci, cells were treated with auranofin, PMX464, and piperlongumine for 3 h and then with CPT (2 μ

[0052] M) Stimulation for 1 hour.

[0053] Figure 3C Shown Figure 3A -B, Experimental flow chart and quantification results of TOPBP1 foci intensity in EdU-positive cells.

[0054] Figure 3D Shown are changes in ATR kinase activity in U2OS cells treated with the indicated concentrations of auranofin as analyzed by immunoblotting.

[0055] Figure 4A Demonstrated detection of RPA2 pS33 and RPA2 by immunostaining and confocal microscopy analysis under physiological conditions

[0056] Foci formation, cells treated with auranofin, PMX464 and piperlongumine for 3 hours, NAC (50 μM)

[0057] in the presence or absence of pre-extraction and fixation.

[0058] Figure 4B Demonstrated detection of RPA2 by immunostaining and confocal microscopy analysis under conditions of replication stress (CPT)

[0059] Formation of pS33 and RPA2 foci in cells treated with auranofin, PMX464, and piperlongumine for 3 h and then stimulated with CPT (2 μM) for 1 h.

[0060] Figure 4C Shown Figure 4A - Quantification of RPA2 pS33 foci intensity in EdU-positive cells in B.

[0061] Figure 4D Shown Figure 4A - Quantification of RPA2 foci intensity in EdU-positive cells in B.

[0062] Figure 4E A schematic diagram showing the operational flow of the SIRF experiment.

[0063] Figure 4F The interaction of RPA1 with nascent DNA (biotinylated EdU) in HeLa cells under different treatment conditions was examined by SIRF analysis.

[0064] Figure 4G The number of PLA foci in each cell was quantified.

[0065] Figure 5A The effects of different doses of auranofin on ARID1A + / + and ARID1A - / - The effects of the assay on the viability of HCT116 cells were investigated and the half maximal inhibitory concentration (IC50) was calculated.

[0066] Figure 5B The results show that different doses of auranofin can induce ARID1A in SW48 cells. + / + and ARID1A - / - The effects on cell viability were investigated and the half-maximal inhibitory concentration (IC50) was calculated and displayed.

[0067] Figure 5C The results show that different doses of auranofin can inhibit ARID1A in OVCAR-3 cells. + / + and ARID1A - / - The effects on cell viability were investigated and the IC50 values ​​were calculated and displayed.

[0068] Fig. 6A The effects of different doses of auranofin on MLH1 in HCT116 cells were shown. + / + and MLH1 - / - The effects on cell viability were investigated and the IC50 values ​​were calculated and displayed.

[0069] Figure 6BThe effects of different doses of auranofin on MLH1 in SW48 cells were shown. + / + and MLH1 - / - The effects on cell viability were investigated and the IC50 values ​​were calculated and displayed.

[0070] Fig. 7A ARID1A + / + and ARID1A - / - Tumor weight changes of HCT116 cell xenografts in NOD / SCID mice treated with auranofin every two days.

[0071] Figure 7B Shown Fig. 7A The quantification graphs of the data shown clearly demonstrate the statistical analysis of tumor weights under different treatment conditions.

[0072] Fig. 8A MLH1 + / + and MLH1 - / - Tumor weight changes of HCT116 cell xenografts in NOD / SCID mice. Mice were treated with auranofin every two days.

[0073] Figure 8B Shown Fig. 8A The quantification graph of the data shown clearly demonstrates the statistical analysis of tumor weights under different treatment conditions. Specific implementation method:

[0074] The present invention is further described below in conjunction with specific embodiments. The described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. It should be understood that the following embodiments are provided to provide a complete disclosure and description of how to use the methods and compositions of the present invention to general professionals in the technical field to which the present invention belongs, and are not intended to limit the scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention.

[0075] Example 1: Study on the tumor inhibition mechanism and pathway of Auranofin

[0076] 1.1 In vitro assay to identify the binding of auranofin to TOPBP1 BRCT7-8 Experimental methods: The biofilm interferometry (BLI) technique was used to study the anti-tumor mechanism and pathway of auranofin. BLI technology was performed using an Octet RED96 instrument (ForteBio). In the binary binding experiment, all purified proteins including TOPBP1 BRCT7-8 / Wt and TOPBP1 BRCT7-8 / F1411A were first biotinylated using EZ-Link NHS-Biotin (Thermo Fisher Scientific) according to the manufacturer's instructions and then added to the SSA biosensor (ForteBio). All proteins reached an average saturated response level of 15 nm within 15 minutes. The protein-loaded sensor was washed in an assay buffer containing PBS, 0.1% BSA, 0.02% Tween-20, and 1% DMSO for 10 minutes to establish a stable baseline, and then began to bind and dissociate with the test compound and DMSO as a reference. The raw kinetic data were processed using the data analysis software provided by the manufacturer using a double reference subtraction method, where a DMSO-only reference and an inactive reference were subtracted, respectively. The association and dissociation rates were fitted using a 1:1 binding model. off With K on The equilibrium dissociation constant (Kd) was calculated from the ratio of

[0077] In the in vitro competition experiments, an assay buffer containing PBS, 0.1% BSA, 0.02% Tween-20 and 1% DMSO was used. Biotin-PHF8_APS (GACFKDAEYIYPSLESDDDDPA) and biotin-pFANCJ (EAEDESIYF(pT)PELYDPEDT) were immobilized on the biosensor surface. During the binding process, TOPBP1 BRCT7-8 / Wt was pre-incubated with a series of auranofin concentration gradients of 0, 1.875, 3.75, 7.5, 15, 30 μM (the concentration gradient was targeted at the ability of auranofin to competitively inhibit the binding of TOPBP1BRCT7-8 / Wt to ​​PHF8_APS) or TOPBP1 BRCT7-8 / Wt was pre-incubated with a series of auranofin concentration gradients of 0, 3.125, 6.25, 12.5, 25, 50 μM (the concentration gradient was targeted at the ability of auranofin to competitively inhibit the binding of TOPBP1 BRCT7-8 / Wt to ​​pFANCJ), followed by a 2-min dissociation in the assay buffer. A 1:1 binding model was used for local fitting to determine the kinetic parameters.

[0078] Experimental results: The researchers purified TOPBP1 BRCT7-8 in vitro and verified the ability of auranofin to bind to it using biofilm interferometry (BLI) technology. The results showed that auranofin has the ability to bind to BRCT7-8 (see Figure 1A In addition, the results of in vitro competitive experiments showed that as the concentration of auranofin increased, the binding ability of TOPBP1 BRCT7-8 to PHF8-APS and pFANCJ gradually weakened, indicating that auranofin can inhibit the binding of PHF8-TOPBP1 and FANCJ-TOPBP1 in vitro ( Figure 1B-1D ).

[0079] 1.2 In vivo experiments verifying the ability of auranofin to disrupt the binding of PHF8-TOPBP1 and FANCJ-TOPBP1 1.2.1 Plasmid transfection experiment Experimental method: Linearized poly(ethyleneimine) (PEI) was used for transfection. When HeLa cells (purchased from ATCC cell bank) grew to 70%, a mixture of plasmid and PEI was added at a ratio of plasmid (μg): PEI: OPTI-MEM = 1:5:100.

[0080] Protein expression and purification Experimental methods: The cDNA fragment of the BRCT 7-8 domain (amino acids 1264 to 1493, Protein Data Bank (PDB) ID: 7CMZ) of TOPBP1 (Gene ID: 11073) was cloned into a modified pET-28a-smt vector. These His-SUMO-tagged proteins were expressed in Escherichia coli BL21 (DE3) strain by induction with 0.15 mM isopropyl-β-D-thiogalactoside overnight at 16°C. The cells were collected by centrifugation and then sonicated in buffer A (25 mM Tris-HCl (pH 8.0), 500 mM NaCl, 10 mM imidazole, 1 mM EDTA, and 1 mM β-mercaptoethanol). Cell debris was removed by centrifugation at 4,000 g for 40 minutes at 4°C. The supernatant was applied to a NiSepharose Excel column (GE Healthcare), and the beads were eluted with buffer A. The fusion protein was eluted with buffer B (25mMTris-HCl (pH 8.0), 500mM NaCl, 200mM imidazole, 1mM EDTA and 1mMβ-mercaptoethanol). The His-tagged protein was cleaved from the SUMO tag by SUMO protease. The de-tagged protein was added to a pre-equilibrated HiTrap SP HP column (GE Healthcare) and eluted with buffer C (20mM MES (pH 6.0), 100mM NaCl, 1mM EDTA and 1mMβ-mercaptoethanol) using a linear gradient of 0.1 to 1.0M NaCl. The eluted protein was concentrated by ultrafiltration and then further purified using a HiLoad Superdex200 16 / 60 gel exclusion column (GE Healthcare) in a buffer containing 20mM MES (pH 6.0), 300mM NaCl and 1mMβ-mercaptoethanol. High purity fractions were collected and concentrated to approximately 40 mg / ml and stored in PBS buffer.

[0081] In order to identify the site where auranofin simultaneously disrupts the binding of TOPBP1 to PHF8 and FANCJ, a mutant (F1411A) BRCT 7-8 mutant protein (F1411A) was constructed, and the expression and purification procedures of the mutant protein were the same as those of the wild-type protein.

[0082] 1.2.2 Immunoprecipitation Experimental Methods: Cell lysates were prepared by incubating cells in NETN buffer (containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.2% Nonidet P-40, 2 mM EDTA) with a mixture of protease inhibitors (Roche) at 4°C for 20 minutes. Subsequently, centrifugation was performed at 14,000 g for 15 minutes at 4°C. For immunoprecipitation, approximately 500 μg of protein was incubated with control or specific antibodies (1-2 μg) at 4°C for 12 hours with rotation; 50 μl of 50% protein G magnetic beads (Invitrogen) were then added and incubation continued for 2 hours. The beads were then washed 5 times with lysis buffer, and between each wash, the beads were precipitated using a magnetic stand (Invitrogen). The precipitated protein was eluted from the beads by resuspending the beads in 2× SDS-PAGE buffer and boiling at 95°C for 10 minutes. Next, SDS-PAGE electrophoresis was performed, followed by immunoblotting.

[0083] Experimental results:

[0084] The present invention transfected FLAG-tagged TOPBP1 plasmid into HeLa cells, and added 0 μM, 1 μM, and 2 μM auranofin for treatment; the effect of auranofin on the binding ability of TOPBP1 with PHF8 and FANCJ was detected by immunoprecipitation technology. The experimental results show (see Figure 2A ), with the increase of auranofin concentration, the binding ability of TOPBP1 to PHF8 and FANCJ weakened.

[0085] At the same time, immunoprecipitation experiments were performed using endogenous TOPBP1 antibodies. The results showed that (see Figure 2B ) The addition of auranofin disrupted the binding of TOPBP1 to PHF8 and FANCJ.

[0086] Two well-known TrxR inhibitors, piperlongumine (Selleck, S7551) and PMX464 (MCE, HY-108534), were used as control groups. HeLa cells were treated with the two well-known TrxR inhibitors at a concentration of 10 μM for 4 hours to detect whether the interaction between TOPBP1 and PHF8 and FANCJ was inhibited. The results showed that only auranofin could affect the binding between TOPBP1 and PHF8 and FANCJ, while piperlongumine and PMX464 could not (see Figure 2CLanes 4-5). It was concluded that auranofin does not rely on the traditional mode of action, that is, it does not regulate the binding of TOPBP1 to PHF8 and FANCJ by inhibiting thioredoxin reductase (TrxR).

[0087] 1.2.3 Molecular docking experiment Experimental method: Auranofin was used as the ligand for molecular docking. All docking simulations were performed using AutoDock 4.2. The crystal structure of TOPBP1 BRCT 7-8 was used as the target conformation for docking (PDB: 7CMZ), and the docking grid was set with the geometric center of APS as the center. The grid diameter was set to approximately 1.8 nm, the grid size was 60×60×60, and the grid spacing was set to 0.375. The size of the docking box was large enough to include potential binding activation pockets. The docked ligand was considered conformationally flexible, and its torsion bond was defined by AutoDock 4.2 based on its chemical features. The final ligand docking mode with the receptor was determined by selecting the position with the lowest binding free energy.

[0088] Experimental results: Molecular docking method revealed that auranofin binds to the F1411 site of TOPBP1. Therefore, in order to identify whether auranofin binds to the F1411 site and simultaneously disrupts the binding of TOPBP1 to PHF8 and FANCJ, this experiment constructed wild-type (Wt) and mutant (F1411A) BRCT 7-8 and confirmed it using BLI experimental technology. The experimental results showed that the F1411 mutation weakened the binding of TOPBP1 to auranofin, indicating that the F1411 site is one of the key sites for the interaction between TOPBP1 and auranofin (see Figure 2D ).

[0089] 1.2.4 Prime editing experiment Experimental method: HeLa cells were transfected with 3μg PE3, 1μg epegRNA and 0.4μg nicking sgRNA plasmids at a density of about 60%. Cells were cultured for 3 days after transfection, and then single clones were sorted by flow cytometry. When the cells reached sufficient density, genomic DNA was extracted, followed by PCR amplification and DNA sequencing.

[0090] epegRNA sequence:

[0091] caccGTGGATCAGTCTCGAGAAGCgttttAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAG

[0092] TCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGgtgcGTTTGGCGCCTGCTTCTCGAGA

[0093] CTAAATTTTGT

[0094] Nicking sgRNA sequence:

[0095] caccgAGAACTCATCATAGCAATCT

[0096] Experimental results: Prime editing was used to mutate F1411 in the genome into A, achieving the mutation of amino acids in the endogenous genome (see Figure 2E Through immunoprecipitation experiments, the researchers found that compared with the DMSO group (control group), under the action of 2μM auranofin (experimental group), the binding ability of endogenous wild-type TOPBP1 to PHF8 and FANCJ decreased (see Figure 2F In endogenous F1411A cells, compared with the DMSO control group, the addition of auranofin did not further weaken the binding of TOPBP1 to PHF8 and FANCJ (see Figure 2F Lanes 4-5). This further proves that TOPBP1 F1411 is the key site for auranofin binding.

[0097] Based on the above experimental results, the researchers can conclude that auranofin disrupts the protein-protein interaction between TOPBP1 and PHF8 and FANCJ by specifically binding to the F1411 site of the TOPBP1 BRCT7-8 domain. This effect is independent of the traditional TrxR inhibition mechanism, providing a new perspective for understanding the pharmacological effects of auranofin and may provide a potential target for the development of new therapeutic strategies. These findings are of great significance for a deeper understanding of the molecular mechanism of auranofin and its application in disease treatment.

[0098] Example 2: Auranofin inhibits the activation of ATR signaling and the accumulation of RPA at damaged replication forks

[0099] This example uses immunofluorescence technology to detect the effect of auranofin on the accumulation of TOPBP1 at the site of injury. It is studied whether auranofin affects the accumulation of TOPBP1 by increasing the levels of oxidized TrxR and ROS. The antioxidant N-acetylcysteine ​​(NAC) and known TrxR inhibitors piperlongumine and PMX464 were used to evaluate their effects on the formation of TOPBP1 foci. The activation of the ATR signaling pathway was detected by treating with different concentrations of auranofin.

[0100] 2.1 Auranofin inhibits the recruitment of TOPBP1 and the activation of ATR signaling under replication stress Experimental methods: Immunofluorescence was used for detection. Cells were plated on glass slides (BD Biosciences), fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. Samples were blocked in 5% donkey serum and stained with appropriate primary and secondary antibodies coupled to Alexa Fluor 488, 594, or 647 (Invitrogen). To avoid the bleed-through effect in double staining experiments, each dye was scanned independently in multi-tracking mode. When detecting nuclear RPA2, RPA1, TOPBP1, or RPA2 pS33 foci, cells were pre-treated with 0.5% Triton X-100 on ice for 5 minutes and fixed with 3% paraformaldehyde and 2% sucrose for 15 minutes at room temperature. Then they were permeabilized with 0.5% Triton X-100 on ice for 5 minutes and blocked in 5% donkey serum for 1 hour at room temperature. For S phase differentiation, cells were treated with 10 μM EdU for 1 hour in a 37°C incubator and then fixed. KeyFluor 647-azide (Keygen Technologies) was used for S phase labeling according to the manufacturer's instructions. Two parallel models were set up in this experiment, one model was a blank control group without 2 μM camptothecin (CPT) treatment, namely the DMSO model group (this group was mainly used to explore the changes in the cellular localization of TOPBP1 under the treatment of drugs such as auranofin under physiological conditions), and the other was a replication stress model group with 2 μM camptothecin (CPT), namely the CPT model group (this group was mainly used to explore the changes in the ability of TOPBP1 to recruit to replication stress sites under the treatment of drugs such as auranofin under replication stress conditions). Experimental groups were set up in each model group: auranofin group, piperlongumine treatment group, PMX464 treatment group, and solvent control group DMSO group.

[0101] Experimental results:

[0102] Based on the information disclosed before the filing date of this application, PHF8 regulates the accumulation of TOPBP1 at the damaged site and the activation of ATR signal by binding to TOPBP1. This example uses immunofluorescence experiments to detect the accumulation of TOPBP1 at the damaged site after 2 μM CPT induces replication stress after auranofin treatment. Figure 3B Column 2 compared to column 1 and Figure 3CCompared with column 6, column 7 shows that the addition of auranofin severely inhibits the accumulation of TOPBP1 signals at the site of injury. In order to further verify whether the phenomenon that the addition of auranofin severely inhibits the accumulation of TOPBP1 signals at the site of injury is caused by auranofin increasing the level of ROS by increasing the oxidized form of TrxR? The researchers simultaneously set up an experimental group with the addition of the antioxidant N-acetylcysteine ​​(NAC) (see figure). The antioxidant N-acetylcysteine ​​(NAC) was used to remove ROS in the cells, and the results are shown in Figure 3B Column 3 compared to column 1 and Figure 3C Compared with column 6, the results in column 8 show that the fluorescence signal of TOPBP1 was not restored by the addition of NAC. Therefore, the result that auranofin inhibited the accumulation of TOPBP1 signal at the damage site was not related to its increase in the oxidized form of TrxR and thus the increase in ROS levels.

[0103] At the same time, the researchers set up two experimental groups treated with TrxR inhibitors (10μM piperlongumine and 10μM PMX464) for 4 hours. Figure 3B Columns 4-5 compared to column 1 and Figure 3C Comparison of columns 9-10 with column 6 shows that treatment for 4 hours does not affect the formation of TOPBP1 foci.

[0104] The researchers induced replication stress by adding 2 μM camptothecin (CPT) for 1 hour, and then treated with different concentrations of auranofin. They found that the activation of ATR signaling (CHK1 pS345, RPA2 pS33 and RPA2 pS4 / 8) was inhibited in a concentration-dependent manner by the addition of auranofin. Figure 3D ).

[0105] 2.2 Experimental method for inhibiting the binding of RPA to damaged chromatin regions by auranofin: The same immunofluorescence experiment and in situ analysis of protein interactions at DNA replication forks (SIRF) experiment as in section 2.1 were used to further study the ability of auranofin to inhibit the binding of RPA to damaged chromatin regions.

[0106] SIRF Experimental Procedure

[0107] 1. EdU incubation and washing: U2OS cells (purchased from ATCC cell bank) were incubated with high glucose medium containing 125 μM EdU for 8 minutes to mark the active DNA synthesis process in S phase. After the incubation, the EdU medium was removed and the slides were washed twice with PBS to remove unbound EdU. Then, medium containing 1 mM HU was added and incubated for 4 hours with or without auranofin or NAC.

[0108] Step 2. Fixation, permeabilization and Click reaction: The cells were first washed with cold PBS and then fixed with 4% paraformaldehyde for 5 minutes to maintain the cell structure. Next, 0.25% Triton X-100 was used for permeabilization for 15 minutes to enhance the penetration of subsequent reagents. After permeabilization, the cells were washed again with PBS to remove the permeabilizing agent. After that, freshly prepared Click reaction mixture was added and incubated at room temperature for 1 hour to detect EdU-labeled DNA.

[0109] Step 3. Blocking, antibody incubation, PLA, and imaging: Block with 10% FBS at 37°C for 1 hour to reduce nonspecific binding. After blocking, cells were incubated with primary antibodies overnight at 4°C to identify the target protein. PLA was performed according to the Duolink In Situ Detection Kit instructions to detect protein-protein interactions. Finally, Fluoroshield coverslips containing DAPI were used for nuclear staining. Images were captured using a Zeiss LSM 900 microscope and quantitatively analyzed using ImageJ software. The specificity of the antibody was verified by knocking out RPA1 to ensure the reliability of the experimental results.

[0110] Experimental results: Based on the information that has been disclosed before the filing date of this application, FANCJ promotes the accumulation of RPA at stalled replication forks by binding to TOPBP1BRCT7-8. The researchers used the same immunofluorescence experiment as in Section 2.1 to detect the changes in the recruitment of RPA2 at replication stress after treatment with 2μM auranofin. The experimental results showed that the addition of auranofin significantly reduced the ability of RPA2 to form foci ( Figure 4B Compare column 2 to column 1 and Figure 4D Compare the 7th column with the 6th column). Two parallel models were set up in this experiment. One model was a blank control group without 2μM camptothecin (CPT) treatment, namely the DMSO model group (this group was mainly used to explore the changes in the cellular localization of RPA2 under the treatment of drugs such as auranofin under physiological conditions), and the other was a replication stress model group with 2μM camptothecin (CPT), namely the CPT model group (this group was mainly used to explore the changes in the ability of RPA2 to recruit to replication stress sites under the treatment of drugs such as auranofin under replication stress conditions). Experimental groups were set up in each model group: auranofin group, piperlongumine treatment group, PMX464 treatment group, and solvent control group DMSO group. Figure 3B -C conclusion is similar, NAC scavenging ROS does not lead to the disappearance of the inhibitory effect of auranofin on RPA recruitment ( Figure 4B Column 3 is compared to column 1 and Figure 4D Column 8 compared to column 6), and TrxR inhibitors such as piperlongumine and PMX464 do not produce the effect of auranofin in inhibiting RPA recruitment ( Figure 4B Columns 4-5 compared to column 1 and Figure 4D Compare columns 9-10 with column 6).

[0111] The in situ analysis of protein interactions at DNA replication forks (SIRF) experiment provides in situ spatial resolution, allowing scientists to observe and analyze the dynamic changes and collaborative working mechanisms of proteins in the natural state of cells, thereby gaining a deeper understanding of the accuracy and efficiency of DNA replication. Based on this experiment, the researchers found that the ability of RPA1 to bind to nascent DNA was reduced after auranofin treatment ( Figure 4F Column 6 is compared with column 5 and Figure 4G Column 6 is compared with column 5). It can be inferred that the addition of auranofin reduces the ability of tumor cells to cope with replication stress and increases the probability of genomic instability in tumor cells. Once the tumor cell DNA damage response system has related gene mutations or gene deletions, such as ARID1A or MLH1 deletions, the tumor cells will be unable to repair DNA damage and eventually die.

[0112] Example 3: Auranofin enhances ARID1A at the cellular level - / - and MLH1 - / - Tumor cell killing ability 3.1 Auranofin enhances inhibition of ARID1A in xenografts - / - Tumor growth

[0113] Experimental methods:

[0114] 3.1.1 Preparation of ARID1A - / - and MLH1 - / - Stable expression cell line: The virus was prepared by linear poly(ethyleneimine) (PEI) transfection method. 293T cells were cultured in a 10 cm culture dish. When the cells grew to 70%, a mixture of plasmids and PEI was added at a ratio of plasmid (μg): PEI: OPTI-MEM = 1:5:100. Plasmids include: packaging plasmids (pMDLg / pRRE, pRSV-REV and pVSVG) and target plasmids (shControl, shARID1A, Control and sgMLH1). Viral supernatants were collected at 48 hours and 72 hours, respectively. The colorectal cancer cell lines HCT116, SW48 and ovarian cancer cell lines OVCAR-3 to be infected were prepared in advance, and a blank control group was kept. After adding the virus solution for 24 hours, the culture medium was replaced with normal culture medium for screening using puromycin or flow sorting.

[0115] 3.1.2. Auranofin enhances ARID1A - / - Tumor cell killing effect

[0116] HCT116 cells expressing shControl and shARID1A constructed in section 3.1.1 were cultured in 96-well plates at 1500 cells / well. After 24 hours, each group of cells was treated with 0, 100 nM, 200 nM, 500 nM, 750 nM, and 1000 nM auranofin and cultured for another 72 hours. Cell Titer Aqueous One Solution Reagent (G3582, Promega) was then added to each well and cultured in a 37°C incubator for 1 hour. Cell viability was determined by measuring the absorbance at 490 nm using a 550 BioRad plate-reader (Bio-Rad, Hertfordshire, UK) and plotted into a survival curve. The results are shown in FIG. Figure 5A As shown in the figure, the survival rate of the shARID1A group (IC50: 306.4nM) was significantly lower than that of the control group shControl cells (IC50: 1395nM), that is, the concentration of auranofin that reached the half-lethal dose of the control group cells was 1395nM, while the concentration of auranofin that reached the half-lethal dose of the experimental group cells was 306.4nM. We can conclude that compared with the control group, in ARID1A - / - The use of low doses of auranofin in HCT116 tumor cells can achieve the effect of tumor inhibition. The experimental method is the same as above. In SW48 cells and OVCAR-3 cells, the researchers reached a consistent conclusion, that is, the survival rate of the shARID1A group in SW48 cells (IC50: 451.8nM) was significantly lower than that of the control group shControl cells (IC50: 1788nM), and the survival rate of the shARID1A group in OVCAR-3 cells (IC50: 622.3nM) was significantly lower than that of the control group shControl cells (IC50: 3353nM), indicating that the use of low doses of auranofin in these two cell lines can also effectively kill ARID1A - / - The ability of cells. Figure 5B-5C ).

[0117] 3.2 Auranofin enhances MLH1 - / - Tumor cell killing effect

[0118] Control and sgMLH1 HCT116 cells were cultured in 96-well plates at 1500 cells / well. After 24 hours, the cells were treated with 0, 100 nM, 200 nM, 500 nM, 750 nM, and 1000 nM auranofin, respectively. After 72 hours, CellTiter Aqueous One Solution Reagent (G3582, Promega) was added to each well and cultured in a 37-degree incubator for 1 hour. The cell viability was determined by measuring the absorbance at 490 nm using a 550 BioRad plate-reader (Bio-Rad, Hertfordshire, UK) and a survival curve was plotted. The results are shown in Fig. 6A As shown, the survival rate of the sgMLH1 group was significantly lower than that of the control group Control cells: the survival rate of the sgMLH1 group (IC50: 436.6nM) was significantly lower than that of the control group Control cells (IC50: 1413nM), that is, the concentration of auranofin that reached the half-lethal dose of the control group cells was 1413nM, while the concentration of auranofin that reached the half-lethal dose of the experimental group cells was 436.6nM. We can conclude that compared with the control group, the use of a low dose of auranofin in sgMLH1 HCT116 tumor cells can achieve the effect of tumor inhibition ( Fig. 6A ). The experimental method was the same as above. The researchers reached a consistent conclusion in SW48 cells, that is, the survival rate of the sgMLH1 group (IC50: 467.5nM) in SW48 cells was significantly lower than that of the control group shControl cells (IC50: 1775nM), indicating that the use of low doses of auranofin in this cell line can also effectively kill MLH1 - / - The ability of cells Figure 6B ).

[0119] Example 4: Using animal models to verify the enhancement of ARID1A by auranofin - / - and MLH1 - / - 1. Auranofin enhances the tumor killing effect of ARID1A in xenografts - / - Tumor growth

[0120] HCT116 cells (1.5×10 6 ), resuspended in 200 μL PBS, and orthotopically transplanted into the subcutaneous tissue of 6-week-old immunocompromised (SCID) female mice. The tumor volume reached 40 mm 3Afterwards, the control group shControl and the experimental group shARID1A were intraperitoneally injected with auranofin (5 mg / kg, 2% v / v dimethyl sulfoxide, 10% v / v HPBCD, 2-hydroxypropyl-β-cyclodextrin, PBS) every two days. Five to six animals were used in each group for the experiment. Tumor volume was measured with a vernier caliper every two days, and the calculation formula was 0.5×length×width. 2 .

[0121] The experimental results are shown in Figure 7A-7B As can be seen from the figure, after treatment with the same dose and the same cycle of auranofin, the tumor weight of mice transplanted with shARID1A was significantly smaller than that of mice transplanted with shControl, which means that the tumors of mice transplanted with shARID1A have a higher therapeutic response to auranofin. In the future, it is possible to identify the genotype of the tumor and use a low dose of auranofin to treat ARID1A - / - Tumor.

[0122] 2. Auranofin enhances inhibition of MLH1 in xenografts - / - Tumor growth

[0123] HCT116 cells (1.5×10 6 ), resuspended in 200 μL PBS, and orthotopically transplanted into the subcutaneous tissue of 6-week-old immunocompromised (SCID) female mice. The tumor volume reached 40 mm 3 Afterwards, the control group and the experimental group were intraperitoneally injected with auranofin (5 mg / kg, 2% v / v dimethyl sulfoxide, 10% v / v HPBCD, 2-hydroxypropyl-β-cyclodextrin, PBS) every two days. Five to six animals were used in each group for the experiment. Tumor volume was measured with a vernier caliper every two days, and the calculation formula was 0.5×length×width. 2 .

[0124] The experimental results are shown in Figures 8A-8B We found that the tumor weight of mice transplanted with sgMLH1 was significantly smaller than that of mice transplanted with Control. This means that the tumors of mice transplanted with sgMLH1 have a higher therapeutic response to auranofin. In the future, we can identify the genotype of the tumor and use low doses of auranofin to treat MLH1 - / - Tumor.

Claims

1. Use of a competitive inhibitor of TOPBP1 in the preparation of a pharmaceutical composition for treating and / or improving tumors, characterized in that: The tumor is selected from: i) Mismatch repair deficient (MMRD) tumors; or ii) ARID1A-deficient tumors.

2. The use according to claim 1, characterized in that: The mismatch modification deficient tumor is an MLH1 deficient tumor.

3. The use according to any one of claims 1-2, characterized in that: The binding site of the competitive inhibitor of TOPBP1 is the BRCT7-8 pocket of TOPBP1.

4. The use according to claims 1-2, characterized in that: The competitive inhibitor of TOPBP1 has the effect of destroying the binding of PHF8-TOPBP1 and FANCJ-TOPBP1.

5. The use according to any one of claims 1 to 4, characterized in that: The competitive inhibitor of TOPBP1 is auranofin.

6. A therapeutic device, characterized in that: Contains modules i) and ii): Module i) is a detection module, and the module i) includes detection reagents required for detecting whether the in vitro sample is ARID1A-deficient or MLH1-deficient; Module ii) is an identification and administration module, wherein the competitive inhibitor of TOPBP1 is administered to the ex vivo sample of the patient identified as ARID1A-deficient or MLH1-deficient in module i).

7. The device according to claim 6, characterized in that The detection reagent in module i) is a biomolecule that specifically hybridizes with the ARID1A or MLH1 gene, an expression product of the ARID1A or MLH1 gene, and / or a detection reagent that uses the ARID1A or MLH1 gene as a detection target.

8. The device according to claim 6 or 7, characterized in that The competitive inhibitor of TOPBP1 has the function of binding to the BRCT7-8 pocket of TOPBP1 or the competitive inhibitor of TOPBP1 has the function of destroying the binding of PHF8-TOPBP1, FANCJ-TOPBP1; preferably, the competitive inhibitor of TOPBP1 is auranofin.

9. Use of a reagent for detecting biomarkers in the preparation of a kit for predicting the anti-tumor efficacy of auranofin, characterized in that: The biomarkers are: i) ARID1A or MLH1 gene; or ii) ARID1A or MLH1 gene expression products.

10. The use according to claim 9, characterized in that: The tumors include colon cancer, lung cancer, endometrial cancer, invasive ductal breast carcinoma, conventional glioblastoma multiforme, ovarian cancer, gastric cancer, bladder cancer, hepatocellular carcinoma, melanoma, and / or colorectal cancer.

Citation Information

Patent Citations

  • Anti-kir antibodies for the treatment of inflammatory disorders

    CN103717619A

  • Advanced drug development and manufacturing

    US20080220441A1

  • Gold complexes as anticancer agent

    US20240059719A1

  • Compositions and methods for determining a treatment course of action

    WO2018127786A1

Cited By

  • Use of auranofin in the preparation of esophageal squamous cell carcinoma treatment drugs

    CN122786372A